Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Mixed Signals from Moderna’s Q3 2024 Performance: Hold Recommendation Issued
Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...